LDLR and pancreatic neoplasm: To enable the exploitation of cell surface LDLR for molecule delivery into pancreatic cancer cells, we used the cyclic VH4127 peptide, bearing non-natural amino acid residues, and which specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR (Supplementary Table S2).